YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[Skyline. Office skyscraper in New York City, Manhattan] ultramarinfoto Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock price…
A month has gone by since the last earnings report for Spyre Therapeutics (SYRE). Shares have lost about 16.6% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue lea…
uniQure N.V. QURE announced that it has submitted a Biologics License Application ("BLA") to the FDA seeking accelerated approval for ifezuntirgene inilparvovec (AMT-130), an investigational gene therapy for the treatment of Huntington's d…
Uniqure stock wavered Wednesday after the Food and Drug Administration accepted its application for approval of a Huntington's gene therapy. Continue Reading
Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled…
A month has gone by since the last earnings report for uniQure (QURE). Shares have added about 17.5% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to i…
(RTTNews) - As Warren Buffett once said, "If you find three wonderful businesses in your life, you'll get very rich." His message underscores the importance of identifying a handful of exceptional companies capable of delivering sustained…
uniQure QURE incurred a second-quarter 2026 loss of $1.22 per share, wider than the Zacks Consensus Estimate of a loss of 81 cents. The loss widened 76.8% year over year, primarily due to higher non-operating and other expenses. Revenues r…
Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as co…
Quick Read Iran conflict escalation, oil surging nearly 8%, and a semiconductor sell-off drove the Dow down 2% and Nasdaq down nearly 2% Wednesday. Goldman Sachs cut Fiverr (FVRR) to Neutral and slashed its target in half to $13, while Blo…
* uniQure (QURE [https://seekingalpha.com/symbol/QURE]) is scheduled to announce Q2 earnings results on Wednesday, July 29th, before market open. * The consensus EPS estimate is -$0.81 [https://seekingalpha.com/symbol/QURE/earnings/estimat…
The market expects Bristol Myers Squibb (BMY) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the com…
uniQure N.V. QURE now represents more than a single-program gene therapy story. Its profile is being reshaped by faster regulatory pathways, a narrower operating model and clinical work in rare neurological diseases. Those trends matter be…
uniQure N.V. QURE has surged as investors reassessed AMT-130, its lead gene therapy candidate for Huntington's disease. The question is whether the move already reflects too much optimism. Valuation, earnings quality, estimate trends and r…
uniQure N.V. QURE remains a catalyst-driven gene therapy stock, with AMT-130 shaping most of the investment debate. The program targets Huntington's disease, an area where disease-modifying options remain absent. Recent FDA feedback, a tar…
Photo by ArtsyBee on Pixabay Your biotech fund just posted a big gain, but the reason why is more about the whole sector than any single star. Twist Bioscience (TWST), at just 2.0% of the fund, rose 55.6% last month, helping to lead a rall…
We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. UniQure N.V. (NASDAQ:QURE) is among the best healthcare stocks. TheFly reported on June 18 that Barclays raised its rating on QURE to Ov…
(RTTNews) - uniQure N.V. (QURE), a healthcare company, priced its previously announced public offering, which has been upsized to approximately $225 million in gross proceeds. The offering of 4.95 million shares was priced at $45.50 per sh…
LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its pre…
(RTTNews) - uniQure N.V. (QURE), a gene therapy company has launched a proposed $150 million underwritten public offering as it looks to strengthen its balance sheet and support ongoing development programs. The company said the offering w…
LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced…
uniQure QURE reported initial six-month follow-up results from the first low-dose cohort of six patients enrolled in its ongoing phase I/IIa study evaluating AMT-260, an investigational gene therapy for the treatment of refractory mesial t…
Shares of uniQure QURE soared 78.4% on June 17, after the company announced a major regulatory milestone for AMT-130, its investigational gene therapy for Huntington's disease. The stock, however, lost 3.9% on June 18. During a recent type…
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s. Previous close: $26.99. An 81% gain, ov…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. uniQure is back in focus after modelled fair value estimates shifted from about US$39.05 to roughly US$52.56, a change that has fed…
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s. Previous close: $26.99. An 81% gain, ov…
SpaceX initiated, Salesforce upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled…
ClearPoint Neuro, Inc. CLPT shares rallied 26% in the last trading session to close at $16.81. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stoc…
(RTTNews) - Today's top gainers included uniQure, which rallied after the FDA softened its stance on the company's investigational gene therapy; Elicio Therapeutics, following encouraging treatment responses from its cancer vaccine in panc…
UniQure NV (NASDAQ:QURE) is one of the 10 Stocks Making Investors Richer. UniQure skyrocketed by 78.44 percent on Wednesday to finish at $48.16 apiece as investors gobbled up shares after the Food and Drug Administration (FDA) approved the…
The S&P 500 Index ($SPX) (SPY) on Wednesday closed down -1.21%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -0.98%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.99%. June E-mini S&P futures (ESM26) fell -1.19%, and…
The S&P 500 Index ($SPX) (SPY) on Wednesday closed down -1.21%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -0.98%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.99%. June E-mini S&P futures (ESM26) fell -1.19%, and…
Gene therapy company uniQure has faced a brutal uphill battle to commercialize its experimental treatment for Huntington’s disease, but its outlook suddenly has brightened. Shares of the Amsterdam-based biopharmaceutical company surged 74%…
The S&P 500 Index ($SPX) (SPY) today is down -0.15%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.23%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.30%. June E-mini S&P futures (ESM26) are down -0.17%, and June E-mini Nasdaq…
In trading on Wednesday, computers shares were relative leaders, up on the day by about 5.6%. Leading the group were shares of AstroNova, up about 70.2% and shares of Nano Dimension Ltd (NNDM) up about 9.8% on the day. Also showing relativ…
Check out some of the companies making the biggest moves midday: SpaceX — The rocket manufacturer dropped more than 3% Wednesday after soaring nearly 50% in its first three days as a public company since its $135-per-share IPO last Friday.…